The same held true for Hb value measured during the follow-up (CKD: biosimilars: mean±SD = 11.4±1.6 g/dL; reference product: mean±SD = 12.3±1.7 g/dL; ESAs covered by patent: mean±SD = 11.8±1.5 g/dL; biosimilars vs reference product: p-value = 0.124; biosimilars vs ESAs covered by patent: p-value = 0.224; Cancer: biosimilars: mean±SD = 11.3±1.7 g/dL; reference product: mean±SD = 11.3±1.7 g/dL; ESAs covered by patent: mean±SD = 11.5±1.8 g/dL; biosimilars vs reference product: p-value = 1.000; biosimilars vs ESAs covered by patent: p-value = 0.515). The gene discussed is GSTM1; the disease is cancer.